Empowered Patient Podcast

Elizabeth Jeffords, Chief Commercial and Strategy Officer and Eva Czirr, Associate Director, Alkahest talk about how they are applying their expertise in age-related and neurodegenerative and cognitive diseases to treating chronic kidney disease particularly end stage renal disease. With a focus on cognitive impairment related to inefficient dialysis, Alkahest is decoding the protein beta-2 microglobulin to determine if alleviation of a massive overload of the protein can benefit patients.

@alkahestinc #CKD #ESRD #B2M

Alkahest.com

Listen to the podcast here

Elizabeth Jeffords, Chief Commercial and Strategy Officer and Eva Czirr, Associate Director, Alkahest talk about how they are applying their expertise in age-related and neurodegenerative and cognitive diseases to treating chronic kidney disease particularly end stage renal disease. With a focus on cognitive impairment related to inefficient dialysis, Alkahest is decoding the protein beta-2 microglobulin to determine if alleviation of a massive overload of the protein can benefit patients.

@alkahestinc #CKD #ESRD #B2M

Alkahest.com

Download the transcript here

Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy. While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations. Avadel's once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing.

@AvadelPharma #narcolepsy #SleepDisorder #EDS #cataplexy

Avadel.com

Listen to the podcast here.

Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy. While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations. Avadel's once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing.

@AvadelPharma #narcolepsy #SleepDisorder #EDS #cataplexy

Avadel.com

Download the transcript here.

Mary Millard, Infection Prevention Advocate, became a patient advocate after suffering acute septic shock from a hospital procedure where she was infected with pseudomonas, a very powerful Gram negative bug, a bacteria that remains in her body. Mary talks about why she is intent on educating healthcare providers about the prevention of hospital acquired infections through better procedures and innovative surfaces. She also describes her work speaking at microbiology and infectious diseases conferences to inform pharmaceutical companies and infectious disease doctors about the need to continue development of antibiotics to treat sepsis infections.

@HAISurvivor

#Sepsis #antibioticresistance #infections #superbugs

MaryMillard.org

Listen to the podcast here

Mary Millard, Infection Prevention Advocate, became a patient advocate after suffering acute septic shock from a hospital procedure where she was infected with pseudomonas, a very powerful Gram negative bug, a bacteria that remains in her body. Mary talks about why she is intent on educating healthcare providers about the prevention of hospital acquired infections through better procedures and innovative surfaces. She also describes her work speaking at microbiology and infectious diseases conferences to inform pharmaceutical companies and infectious disease doctors about the need to continue development of antibiotics to treat sepsis infections.

@HAISurvivor

#Sepsis #antibioticresistance #infections #superbugs

MaryMillard.org

Download the transcript here

Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance. Michele also speaks to how Recce® 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis.

@ReccePharma $RCE

#antibioticresistance #syntheticantibodies #infections #superbugs #sepsis

Recce.com.au

Listen to the podcast here.

Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance. Michele also speaks to how Recce® 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis.

@ReccePharma

#antibioticresistance #syntheticantibodies #infections #superbugs #sepsis

Recce.com.au

Download the transcript here.

Seth Lederman, MD, Chief Executive Officer and Founder, Tonix Pharmaceuticals brings us up to speed on the work at Tonix in developing new COVID-19 vaccines based on their live, synthetic horsepox vector system with a focus on vaccinating the subgroup of healthy people who are not pregnant and have a working immune system. Seth talks about the advantages of using live replicating virus vaccines as well as how immuno-oncology is informing their approach to stimulating T-cells to fight infectious diseases. In addition, new medicines are being developed to treat fibromyalgia and PTSD.

@TonixPharma

#COVID19 #vaccines #PTSD #fibromyalgia #pain

TonixPharma.com

Listen to the podcast here

Seth Lederman, MD, Chief Executive Officer and Founder, Tonix Pharmaceuticals brings us up to speed on the work at Tonix in developing new COVID-19 vaccines based on their live, synthetic horsepox vector system with a focus on vaccinating the subgroup of healthy people who are not pregnant and have a working immune system. Seth talks about the advantages of using live replicating virus vaccines as well as how immuno-oncology is informing their approach to stimulating T-cells to fight infectious diseases. In addition, new medicines are being developed to treat fibromyalgia and PTSD.

@TonixPharma

#COVID19 #vaccines #PTSD #fibromyalgia #pain

TonixPharma.com

Download the transcript here